The purpose of this study is to determine if the combination of 2007RD01, a natural extract, and saw palmetto lipidic extract, is more effective at treating lower urinary tract symptoms associated with benign prostatic hyperplasia than saw palmetto lipidic extract alone.

Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals

Active Comparator: Control

Dietary Supplement: Saw palmetto lipidic extract

Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals

Eligibility

Ages Eligible for Study:

50 Years to 75 Years (Adult, Senior)

Genders Eligible for Study:

Male

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patient must be an adult man aged between 50 and 75

Patient must have Benign Prostatic Hyperplasia symptoms

Exclusion Criteria:

Patient has a malfunction of the urinary tract, is suffering from acute urinary retention, or is suffering from prostate cancer or urinary tract infection

Patient has been subjected to surgery of the prostate, bladder or urethra

Patient has taken a 5-alpha-reductase inhibitor in the 6-month period preceding screening

Patient has taken an alpha-blocker in the 2-week period preceding screening

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00797394